We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genetic Marker May Help Predict Risk of Ovarian Cancer
News

Genetic Marker May Help Predict Risk of Ovarian Cancer

Genetic Marker May Help Predict Risk of Ovarian Cancer
News

Genetic Marker May Help Predict Risk of Ovarian Cancer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genetic Marker May Help Predict Risk of Ovarian Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Yale researchers had previously identified the gene known as KRAS-variant as valuable genetic marker to predict the risk of developing deadly ovarian cancer for women, however there had been conflicting evidence of its value in another study.

“This is more confirmatory evidence that this genetic test could aid women at risk of developing ovarian cancer by allowing them to make informed decisions about their health,” said Joanne B. Weidhaas, a study author and associate professor of therapeutic radiology who led the team that originally discovered the KRAS-variant.

An independent team of researchers led by scientists from Ohio State University looked for the variant in a group of women who had been diagnosed with both ovarian and breast cancer and also did not possess any other known markers for these cancers. The study found 39 percent of women in the study possessed the variant.

Other studies have also shown that the variant predicts how well patients respond to standard forms of chemotherapy and the outcome of their disease.

Advertisement